Appointment of Roy Davis as Non-Executive Director
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing innovative sexual health products, today announces the appointment of Roy Davis as a Non-Executive Director with immediate effect.
Roy brings a wealth of commercial experience in medical devices companies and has a proven track record of successfully scaling companies and delivering substantial value for shareholders. He has held leadership positions at a number of publicly quoted med tech companies, including CEO of Optos plc, a leading retinal imaging device manufacturer, from 2008 to 2016 until its sale to Nikon for £259m in February 2015. From 2007 to 2008, Roy was CEO of Gyrus Group plc, a leader in minimally invasive surgery and visualisation, until its acquisition by Olympus Corporation in 2008 for $1.9 billion.
He is currently Non-Executive Chair at LungLife AI plc, Foster and Freeman (the trading name of the Galton group of companies) and Rair Health Ltd and was until recently, Non-Executive Chair at Medica Group plc until its acquisition by IK Partners for £269 million earlier this year. On 7 December it was announced that Roy will become a Non-Executive Director and Chair Designate of Inspiration Healthcare Group plc with effect from 25 January 2024.
Jeff Needham, Chairman of Futura Medical said: "Roy brings with him significant commercial expertise and a proven track record of creating substantial shareholder value. His appointment will add to the depth and breadth of experience of the Futura Board as we continue to monetise our key asset, Eroxon, move towards profitability, and deliver on our strategy."
Roy Davis, said: "I am delighted to be joining the Board of Futura. The Company is providing novel solutions in the sexual health sector and has exciting opportunities ahead of it. I look forward to working with the Board and Executive Team to help execute the strategy and deliver shareholder value."
In accordance with Schedule 2 (g) of the AIM Rules for Companies, Gordon Roy Davis (aged 67 years) holds/has held the following directorships/partnerships in the last five years:
| Current directorships/partnerships | Previous directorships/partnerships (last five years) |
| LungLifeAI, Inc Rair Health Limited Galton Bidco Limited Galton Midco Limited Galton Topco Limited Galton Tradeco Limited | Medica Group plc Edinburgh Molecular Imaging Limited |
Roy Davis currently holds no ordinary shares in the Company.
There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.